ANNEXIN PHARMACEUTICALS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.27 SEK | -3.23% |
|
-15.36% | +3.85% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | 39.6M 3.69M | Capitalization | 96.7M 9.01M |
|---|---|---|---|---|---|
| Net income 2024 * | -52M -4.85M | Net income 2025 * | -16M -1.49M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 18.4M 1.71M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.44 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 14.41% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.23% | ||
| 1 week | -15.36% | ||
| Current month | -10.00% | ||
| 1 month | -1.46% | ||
| 3 months | +6.30% | ||
| 6 months | -57.55% | ||
| Current year | +3.85% |
1 week
0.25
0.32
1 month
0.250.34
Current year
0.200.34
1 year
0.201.17
3 years
0.202.35
5 years
0.203.30
10 years
0.2013.20
| Managers | Title | Age | Since |
|---|---|---|---|
Anna Frostegård
FOU | Founder | 51 | 13-12-31 |
| Chief Executive Officer | 63 | 17-12-31 | |
| Director of Finance/CFO | 53 | 23-04-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 20-12-31 |
Mårten Österlund
BRD | Director/Board Member | 67 | 20-12-31 |
| Chief Executive Officer | 63 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.27 | -3.23% | 22 862 |
| 24-05-16 | 0.279 | -2.11% | 616,381 |
| 24-05-15 | 0.285 | -2.73% | 79,883 |
| 24-05-14 | 0.293 | -7.28% | 535,815 |
| 24-05-13 | 0.316 | -0.94% | 372,596 |
Delayed Quote Nasdaq Stockholm, May 17, 2024 at 04:22 am EDT
More quotes
Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâs main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.85% | 9.04M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.44% | 22.28B | |
| -11.90% | 22.41B | |
| -4.59% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- ANNX Stock
